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Purpose. To investigate the iTRAQ-based proteomic changes of visual cycle-associated proteins in RPE of rd12 mice before and after
RPE65 gene delivery. Mehtods. The right eyes of rd12 mice underwent RPE65 gene delivery by subretinal injection at P14, leaving the
left eyes as control. C57BL/6J mice were served as a wide-type control group. ERGs were recorded at P42, and RPE-choroid-sclera
complex was collected to evaluate the proteomic changes in visual cycle-associated proteins by iTRAQ-based analysis. Western blot
was used to confirm the changes in the differentially expressed proteins of interest. Results. ERG parameters improved dramatically
at P42 after RPE65 delivery. The proteomics analysis identified a total 536 proteins with a global false discovery rate of 0.21%, out of
which 7 were visual cycle-associated proteins. RALBP-1, RBP-1, and IRBP were reduced in the untreated rd12 eyes and the former two
were improved after gene therapy, confirmed by Western blot analysis. Conclusions. RPE65 gene delivery restored retinal function
at P42 and modified the expression of other functional proteins implicated in the visual cycle. The level of RALBP-1 was still below
the normal level after gene therapy in rd12 mice, which may explain the delayed dark adaption in LCA patients undergoing similar
therapy.

1. Introduction
Vertebrate vision is initiated by the activation of the phototransduction cascade in rod and cone photoreceptor cells
of the retina when photons are absorbed by the ubiquitous
chromophore 11-cis-retinal and converted to its all-transisomer [1]. Continued function of photoreceptors requires
removal of the all-trans-retinal and resupply with chromophore [2]. The classical visual cycle regeneration pathway
takes place mostly in the retinal pigment epithelium (RPE)
and uses a key enzyme, retinoid isomerase, to supply 11-cisretinal for both rod and cone photoreceptors using all-transretinoid substrates either recycled from photoreceptors as
vision byproducts or originating from the choroidal blood

supply [3]. The RPE65 protein is the indispensable retinoid
isomerase of the canonical RPE visual cycle and it is highly
and preferentially expressed in the RPE cells [4–7]. Mutations
in the RPE65 gene cause Leber’s congenital amaurosis (LCA),
a hereditary retinal degeneration most often transmitted with
an autosomal recessive pattern of inheritance [8, 9]. LCA
is a blinding disease with an estimated prevalence of about
1 : 80,000 [10]; mutations in more than a dozen genes can
cause LCA and RPE65-LCA is thought to represent about 6%
of all LCA cases [11].
Retinal degeneration 12 (rd12) mouse model is an LCA
animal model with a nonfunctional RPE65 protein because
of a mutation in the RPE65 gene [12, 13]. The absence of
a functional RPE65 protein interferes with the visual cycle

2
and leads to substantial reduction in 11-cis-retinal levels and
accumulation of retinyl esters in RPE, which gradually exerts
a toxic effect on the retinal photoreceptors and severely
affects the visual function. However, histologically rd12 mice
show predominantly cone degeneration while rods appear
to be intact with normal expression of rhodopsin and rod
transducin at early ages, indicating that it might be the lack of
the chromophore 11-cis-retinal that leads to a nonrecordable
rod ERG response at the early stages of the disease [14].
RPE65-associated LCA recently gained recognition due to the
apparent early success achieved in three clinical trials using
gene therapy and recombinant adenoassociated virus (AAV)
vectors [15–17]. Nine LCA patients received a subretinal
injection with an AAV vector and demonstrated partially
restored local visual function, with local visual sensitivity
improved by ∼50-fold in cones and ∼63000-fold in rods
[15–17]. However, this reconstituted vision cycle was not
completely normal but showed slow rod kinetics, resulting
in prolonged course of dark-adaptation and decreased visual
ability after photobleaching, indicating that the recycling of
the retinal chromophore was still abnormal [17]. Currently,
most studies are focused on changes in the RPE65 protein,
but that may be insufficient to explain this problem. There are
several proteins implicated in visual chromophore recycling,
but currently there are no reports of changes in these visual
cycle-associated proteins as a result of gene therapy.
The present study aims to explore the changes in these
proteins after RPE65 gene delivery, using rd12 mice, an
LCA model caused by a mutation in the RPE65 gene. In
our previous work, we used the same model to explore
the proteomic differences occurring in the retina after gene
therapy using two-dimensional electrophoresis (2-DE) and
mass spectrometry [18]. In this study, we collected tissue samples containing RPE (retina-pigment epitheliumchoroid-sclera complex, RPE/Ch/Sc) in rd12 mice at P42, 4
weeks after AAV subretinal injection. This enabled us to do
quantified proteomic study of visual cycle-associated proteins
in the RPE, using a more accurate and sensitive technique
in protein quantification, the isobaric tagging for relative
and absolute protein quantification (iTRAQ) [19, 20]. Seven
visual cycle-associated proteins were identified in rd12 mice.
Three of them, RALBP-1, RBP-1, and IRBP, were differentially
expressed before and after gene therapy.

2. Materials and Methods
2.1. Animals. Twelve rd12 mice (Rpe65 rd12 or B6(A)-Rpe65
rd12/J) were purchased from the Jackson Laboratory (Bar
Harbor, ME), and 6 age-matched C57BL/6J mice were obtained from Animal Center of Wenzhou Medical University.
All mice were bred and maintained in the Animal Facilities
of Wenzhou Medical University. They were kept in a 12hour light-12-hour dark cycle with an ambient light intensity
of 18 lux. All experiments were approved by the Wenzhou
Medical University’s Institutional Review Board and were
conducted in accordance with the ARVO Statement for the
Use of Animals in Ophthalmic and Vision Research. Three
groups were assigned in the experiment: the treated right
eyes of rd12 mice were set as the treated rd12 group, the
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contralateral untreated left eyes were untreated rd12 group,
and both eyes of age-matched wide-type C57BL/6J mice were
the normal control group.
2.2. Gene Therapy. The scAAV5-smCBA-hRPE65 vector as
used in previous studies was used to deliver RPE65 gene in
rd12 mice, with the same method of subretinal injections
at age P14 [18, 21, 22]. Animals were prepared with pupil
dilation and general anesthesia. A 30.5-gauge disposable
needle was used to make a small incision in the cornea
within the pupil area. Then a 33-gauge, unbeveled, blunt
needle mounted on a 5 𝜇L syringe (Hamilton Co., Reno,
NV) was introduced through the corneal incision to reach
the subretinal space in the inferior central region, avoiding
touching the lens and penetrating the neuroretina. One
microliter of vector suspension (1 × 1013 genome containing
particles/mL) containing 1% fluorescein was injected slowly
in the subretinal space in the right eye of rd12 mice. The
injected retinal area was visualized by fluorescein positive
subretinal blebs demarking the retinal detachment and more
than 95% retinal detachment indicates successful injection.
After injection, 1% atropine eye drops and 0.3% tobramycindexamethasone eye ointment (Alcon Laboratories Inc., Fort
Worth, TX) were given 3 times a day for 3 days. Animals
with any complications, including iris-cornea adhesion, iris
or retinal hemorrhage, and lens injury, were excluded from
the experiment.
2.3. Electroretinograms. Scotopic and photopic ERGs at ages
P14 and P42 were recorded. Full-field ERGs were recorded
with a custom-built Ganzfeld dome connecting to a computer
based system (Q450SC UV; Roland Consult, Wiesbaden,
Germany). Six LED stimuli intensities of −35, −25, −15, −5,
5, and 15 cd⋅s/m2 were applied under scotopic conditions,
and 2 white LED stimuli intensities (1 cd⋅s/m2 , 1.96 cd⋅s/m2 )
with a background of 30 cd/m2 were used under photopic
conditions. After dark adaption overnight, scotopic ERG
was always recorded between 8 AM and 11 AM, followed
by photopic ERG. All testing was performed in a climatecontrolled, electrically isolated dark room under dim red
light illumination. Systemic anesthesia was achieved by the
intraperitoneal administration of a mixture of ketamine
(72 mg/kg) and xylazine (4 mg/kg) and 0.5% proparacaine
hydrochloride used to ensure full corneal anesthesia. A small
amount of 2.5% methylcellulose gel was applied to the eye,
and a special Ag/AgCl wire loop electrode was placed over the
cornea as an active electrode. Needle reference and ground
electrodes were inserted into the cheek and tail, respectively.
Recordings were started from the dimmest light intensity to
the brightest. Body temperature was maintained by placing
the animals on a 37∘ C warming pad during the experiment.
2.4. Protein Sample Preparation. After retinas were dissected
from enucleated eyes, the RPE/Ch/Sc complex was extracted,
homogenated, and then mixed with 100 𝜇L ice-cold lysis
buffer (7 M urea, 2 M thiourea, 4% CHAPS, 2 M TBP, 20 mM
Tris-HCL, 1% IEF buffer, 1 mM PMSF, 100 𝜇g/mL DNase,
and 100 𝜇g/mL RNase). The supernatant was obtained after
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centrifugation at 15,000 rpm for 15 minutes at 4∘ C. Protein
concentrations were determined by BCA assay. Equal protein
amount (100 𝜇g) in each group sample was applied to conduct
the subsequent iTRAQ.
2.5. iTRAQ Labeling and Strong Cationic Exchange (SCX)
Fractionation. Following the iTRAQ protocol (Applied Biosystems, Foster City, CA), each 100 𝜇g protein was digested
with 0.2 mL of a 50 𝜇g/mL trypsin (Promega, Madison,
WI, USA) at 37∘ C for 16 h. Peptides were labeled with
isobaric tags 118 (normal control group), 119 (untreated
rd12 group), and 121 (treated rd12 group) and incubated at
room temperature for 2 h. Then the labeled mixtures were
dried by vacuum centrifugation, desalted with Sep-Pak Vac
C18 cartridge 1 cm3 /50 mg (Waters, USA), and fractionated
using a ShimazuLC-20AB HPLC Pump system (Shimazu,
Japan) connected to a strong cation exchange (SCX) column
(polysulfoethyl column, 2.1 mm × 100 mm, 5 𝜇m, 200 Å, The
Nest Group, Inc. USA). SCX separation was performed using
a linear binary gradient of 0–45% buffer B (350 mM KCl,
10 mM KH2PO4 in 25% ACN, pH 2.6) in buffer A (10 mM
KH2PO4 in 25% ACN, pH2.6) at a flow rate of 200 𝜇L/min
for 90 min, and 30 fractions were collected every 3 min. Each
fraction was dried down and redissolved in buffer C (5% (v/v)
acetonitrile and 0.1% formic acid solution), and the fractions
with high KCl concentration were desalted with PepClean C18 spin Column (Pierce, USA).
2.6. LC-ESI-MS/MS Analysis. Each fraction was resuspended
in buffer A (2% ACN, 0.1% FA) and centrifuged at 20,000 ×g
for 10 min. In each fraction, the final concentration of peptides was approximately 0.25 𝜇g/𝜇L. Using an autosampler,
20 𝜇L of supernatant was loaded onto a 2 cm C18 trap column
(inner diameter 200 𝜇m) on a Shimadzu LC-20AD nanoHPLC. Peptides were eluted onto a resolving 10 cm analytical
C18 column (inner diameter 75 𝜇m) that was assembled inhouse. The samples were loaded at 15 𝜇L/min for 4 min and
eluted with a 44 min gradient at 400 nL/min from 2 to 35% B
(98% ACN, 0.1% FA), followed by a 2 min linear gradient to
80% B, maintenance at 80% B for 4 min, and finally a return
to 2% B over 1 min.
The peptides were subjected to nanoelectrospray ionization followed by tandem mass spectrometry (MS/MS)
in an LTQ OrbitrapVelos (Thermo) coupled in-line to the
HPLC. Intact peptides were detected in the Orbitrap. Peptides
were selected for MS/MS using the high-energy collision
dissociation (HCD) operating mode with a normalized collision energy setting of 45%. Ion fragments were detected
in the LTQ. A data-dependent procedure that alternated
between one MS scan followed by eight MS/MS scans was
applied for the eight most abundant precursor ions above
a threshold ion count of 5,000 in the MS survey scan with
the following Dynamic Exclusion settings: repeat counts:
2; repeat duration: 30 s; and exclusion duration: 120 s. The
applied electrospray voltage was 1.5 kV. Automatic gain control (AGC) was used to prevent overfilling of the ion trap;
1 × 104 ions were accumulated in the ion trap to generate
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HCD spectra. For MS scans, the m/z scan range was 350 to
2,000 Da.
2.7. Database Search and Bioinformatics. The resulting
MS/MS spectra were searched against the International
Protein Index (IPI) mouse sequence databases (version
3.45) with MASCOT software (Matrix Science, London, UK;
version 2.2). Protein identification and quantification for
iTRAQ experiments were carried out using the ProteinPilot
software v3.0 (Applied Biosystems, USA). The Paragon
algorithm in ProteinPilot software was used as the default
search program with trypsin as the digestion agent and
cysteine modification of methyl methanethiosulfonate. The
search also included the possibility of more than 80 biological
modifications and amino acid substitutions of up to two
substitutions per peptide using the BLOSUM 62 matrix.
Only proteins identified with at least 95% confidence, or a
ProtScore of 1.3, were reported. A 1.3-fold change was used as
the benchmark. All proteins that showed significantly altered
expression levels went through Ingenuity Pathway Analysis
software (IPA) for pathway and network analysis.
2.8. Western Blot Validation. Western blot analyses were
performed to validate the differentially expressed proteins.
Every two samples in each group were mixed in one Western
blot experiment, which was repeated for three times. Protein
was extracted with lysis buffer and centrifuged to obtain
the supernatant and determine the protein content by BCA
assay. Each of the protein samples (30 𝜇g) was subjected
to SDS-PAGE and then transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad, Hercules, CA). The
membranes were blocked for 1 h at room temperature with
5% nonfat dried milk in Tris-buffered saline containing
0.1% Tween 20 (TBST, Applygen Gene Technology Corp).
Then they were probed overnight with primary anti-RALBP1 (ab166655, Abcam, MA, USA, 1 : 1000) and anti-RBP-1
(ab154881, Abcam, MA, USA, 1 : 2000), followed by incubation with horse radish peroxidase (HRP) conjugated goat
anti-mouse IgG (Santa Cruz Biotechnology, Santa Cruz,
CA, 1 : 2500). Then they were developed with an enhanced
chemiluminescence detection kit (Pierce Biotechnology, Inc.,
Rockford, IL). 𝛽-actin was used as a loading control.
2.9. Statistical Analysis. Results for continuous variables with
normal distributions are presented as means ± standard
deviations (SD). Nonpaired Student’s 𝑡-test was used to
compare means between two groups. Statistical analyses were
conducted with SPSS 18.0 (SPSS, Chicago, IL, USA), and a
two-tailed 𝑃 < 0.05 was considered significant.

3. Results
3.1. Electroretinography (ERG) Responses. The untreated rd12
eyes showed extremely low or even undetectable a-wave
and b-wave peaks under scotopic and photopic conditions,
indicating severely affected retinal function. Four weeks after
AAV injection, a-wave amplitude of the treated rd12 eyes
increased to 210.83 ± 26.70 𝜇V (40-fold of the untreated rd12
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Figure 1: ERG records of untreated rd12, treated rd12, and normal control C57BL/6J eyes. (a) Scotopic ERG of the 3 groups at P42; (b) photopic
ERG at P42. (c) and (d) represent statistical comparison of a-wave and b-wave amplitudes among the different groups at P42 under scotopic
and photopic conditions. The untreated rd12 eyes showed extremely low a-wave and b-wave response in both scotopic and photopic ERGs.
The treated rd12 eyes had great improvement in both a-wave and b-wave amplitudes with normal peak time, close to the wide-type control
levels. NS: no significance. ∗ 𝑃 < 0.05; ∗∗ 𝑃 < 0.001.

level, 𝑃 < 0.001), close to the 284.50 ± 18.95 𝜇V of the
wild-type mice (74.11%, 𝑃 = 0.001) in scotopic ERG with
normal peak time; b-wave amplitude increased to 590.00 ±
57.59 𝜇V (48-fold of the untreated rd12 level, 𝑃 < 0.001),
also approaching the 797.67 ± 89.59 𝜇V of the wild-type
mice (73.97%, 𝑃 = 0.002) with normal peak time (Figures
1(a) and 1(c)). Photopic ERG signals showed similar trend
(Figure 1(b)). Photopic a-wave amplitude of the treated rd12
eyes improved dramatically to 15.32 ± 2.96 𝜇V (4-fold of the
untreated rd12 level, 𝑃 < 0.001) and was not different from
the amplitude recorded from wide-type eyes (13.38 ± 3.43 𝜇V,
𝑃 = 0.363); b-wave amplitude also improved to 84.50 ±
11.99 𝜇V (5-fold of the untreated rd12 level, 𝑃 < 0.001) and
was similar to the wide-type level (91.12 ± 10.62 𝜇V, 𝑃 =
0.377) (Figure 1(d)). This is in accordance with our previous
findings [18] and supports the notion that gene therapy could
restore retinal function in this animal model.

3.2. Identification and Quantitation of Differentially Expressed
Proteins after AAV Injection. We used iTRAQ proteomics
to identify and quantify proteins 4 weeks after RPE65
gene delivery in rd12 mice, compared with the untreated
rd12 and normal control C57BL/6J mice. A total of 14432
unique peptides were identified, corresponding to a set of
610 proteins with more than 95% confidence (ProtScore >
1.3, global false discovery rate (FDR) = 0.21%). Of these
610 proteins, 536 were identified with relative quantization,
in which 7 were identified as visual cycle-associated proteins including retinaldehyde-binding protein 1 (RALBP1), retinol-binding protein 1 (RBP-1), interphotoreceptor
retinoid-binding protein (IRBP), retinal dehydrogenase 2
(RDH-2), retinal dehydrogenase 5 (RDH-5), lecithin retinol
acyltransferase (LRAT), and ezrin-radixin-moesin-binding
phosphoprotein 50 (EBP-50) (Table 1). Of these proteins,
the expressions of RALBP-1, RBP-1, and IRBP were reduced
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Table 1: The identification and quantification of the visual cycle-associated proteins.
Unused ProtScore %Cov

Protein name

7.74
8.77
11.16
2
41.2
2
8.09

Retinaldehyde-binding protein 1
Retinol-binding protein 1
Interphotoreceptor retinoid-binding protein
Retinal dehydrogenase 2
Retinal dehydrogenase 5
Lecithin retinol acyltransferase
Ezrin-radixin-moesin-binding phosphoprotein 50

by at least 0.68-fold in the untreated rd12 mice relative
to the pooled sample of wild-type tissues, while the other
four proteins (RDH-2, RDH-5, LRAT, and EBP-50) showed
normal levels of expression. In the treated rd12 eyes, RALBP-1
increased about 6-fold compared to the levels of the untreated
rd12 samples, although it was still lower (66.1%) than the
one observed in the samples from wild-type mice. The levels
of RBP-1 were also considerably increased in treated rd12
samples, a 2-fold increase compared to the untreated rd12
levels and 1.5-fold increase compared to the levels in wildtype mice. In contrast, the expression of IRBP did not
increase on P42, and the level in the treated mice was slightly
lower (83.2%) compared to the untreated mice (Figure 2).
In addition, in the 536 relatively quantified proteins, 91
were downregulated and 71 were upregulated by 1.3-fold in
untreated rd12 eyes compared to the wide-type levels (see
Supplementary Tables 1(a) and 1(b) in Supplementary Material available online at http://dx.doi.org/10.1155/2015/918473).
3.3. Confirmation of Differentially Expressed Proteins. Western blot analysis was performed to validate the changes
observed in the differentially expressed visual cycle-related
proteins before and after gene therapy. The results confirmed
that the expression of RALBP-1 and RBP-1 was much weaker
in the untreated rd12 eyes and that gene therapy increased
their level similar to that in the normal C57BL/6J mice
(Figure 3).

Untreated
rd12/B6
(119 : 118)

Treated rd12/B6
(121 : 118)

2
5
5
1
1
1
4

0.1159
0.6792
0.6368
0.9727
1.0864
0.912
0.9638

0.6607
1.4997
0.5297
1.1066
1.0186
0.9285
0.912

2

Relative quantitation

47
68.5
34.8
22.4
22.4
63.6
36.9

Peptides (95%)

1

0
RALBP-1

RBP-1

IRBP

B6
Treated rd12
Untreated rd12

Figure 2: Identification and quantification of differentially
expressed proteins by iTRAQ. The RALBP-1, RBP-1, and IRBP
were identified as differentially expressed visual cycle-associated
proteins among the untreated rd12, treated rd12, and normal
control C57BL/6J eyes. RALBP-1, RBP-1, and IRBP were remarkably
reduced in the untreated rd12 mice (<0.7×) compared to those of
C57BL/6J sample. In the treated rd12 eyes, RALBP-1 was increased
to 6-fold of the untreated rd12 level, although it was still lower than
the normal level (0.66-fold); RBP-1 was increased to 2-fold of the
untreated rd12 level and 1.50-fold of the normal level. IRBP level
was still lower in the treated rd12 eyes.

4. Discussion
Gene therapy by subretinal administration of scAAV5smCBA-hRPE65 vector is a safe and effective treatment to
rescue rod and cone photoreceptor function in rd12 mice,
as demonstrated previously [18, 21, 22]. The current investigation focuses on the changes of the visual cycle-associated
proteins in rd12 eyes before and after gene therapy, using
the technique of iTRAQ-based 2D LC-MS/MS. Seven visual
cycle-associated proteins in RPE layer were identified by this
analysis. Three of the seven proteins, RALBP-1, RBP-1, and
IRBP, were found to be downregulated in the RPE of rd12 eyes.
Subretinal delivery of RPE65 by gene therapy demonstrated
normalization of the levels of RALBP-1 and RBP-1, while no
positive effect was observed on the levels of IRBP.

Visual cycle (or retinoid cycle) is the process by which
11-cis-retinal is regenerated from all-trans-retinal after photoisomerization, and it mainly takes place in the RPE layer.
After conversion from all-trans-retinyl ester to 11-cis-retinol
by isomerase, RALBP-1 acts as an acceptor of 11-cis-retinol
to produce 11-cis-retinal and fulfill the visual cycle [23, 24].
RALBP-1 is another essential protein in the isomerization
reaction of the visual cycle, and it plays a critical role to
sustain normal retinal function and dark adaptation [25].
Our results demonstrated that the levels of RALBP-1 were
dramatically reduced in rd12 mice, and RPE65 gene delivery
not only regenerated the isomerase RPE65 but also increased
the production of RALBP-1, leading to visual cycle restoration
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Figure 3: Western blot analysis of differentially expressed proteins. (a) The expression of RALBP-1 and RBP-1 was weak in the untreated rd12
eyes and appeared to increase significantly following gene therapy to levels similar to those present in normal wild-type control eyes. (b) and
(c) show the relative grayscale of RALBP-1 and RBP-1 compared to the wild-type values.

and normalization of the visual function. The incomplete
recovery of RALBP-1 expression in treated rd12 eyes may help
to explain why the dark adaption was still delayed after similar
therapy in LCA patients. Thus, a supplementation of RALBP1 protein by certain treatment might be a strategy to solve this
problem.
IRBP is a large glycoprotein synthesized in the photoreceptors and situated in the interphotoreceptor matrix
[26]. It functions as a retinoid-transport vehicle to facilitate
the exchange of 11-cis-retinal, 11-cis-retinol, and all-transretinol between the RPE, photoreceptors, and Müller cells
[27, 28]. Despite some histological and electrophysiological
changes because of cytotoxic effects of large amounts of free
retinoids, the absence of IRBP in IRBP−/− mice did not cause
gross abnormalities in the visual cycle [29]. In this study,
the expression of IRBP in rd12 mice was decreased, which
might be attributed to the negatively affected function of the
photoreceptors. RPE65 gene delivery can restore rod and cone
function; however, the production of IRBP was not increased
and even slightly lower levels were detected compared to
pretreatment. One possible explanation for this finding might
be that the distribution of IRBP could be influenced by the

retinal reattachment after temporary detachment caused by
subretinal injection.
RBP-1 is localized in the RPE and serves as a chaperone of
all-trans-retinol to LRAT in the visual cycle. RBP-1 has been
recognized as a pigment epithelium derived factor which
supports photoreceptor health and structural integrity [30].
In our results, the production of RBP-1 was reduced in
rd12 mice, suggesting that the RPE function might also be
influenced by photoreceptor integrity. Gene therapy could
increase the expression of RBP-1 in the RPE substantially,
indicating that RBP-1 could resume its function to transport
all-trans-retinol once the process of retinol recycling is
recovered. The other four visual circle-associated proteins
including LRAT, RDH-2, RDH-5, and EBP-50 were found to
remain at relatively normal expression levels in the RPE of
rd12 mice, demonstrating that not all proteins implicated in
vision cycle were affected by the lack of RPE65 function.
The fate of the visual cycle proteins in LCA animal
models deserves further investigation since it may reveal
unrecognized aspects of the disease process and provide
important indications to further improve the visual function
in LCA patients after gene therapy. One limitation in this
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study is that only one time point (P42) after gene therapy
was tested. The results could be more informative if earlier
(P21) and longer time point (P98) analyses were included.
Besides, the dark-adapted ERG seems normal in treated rd12
eyes, so the ERG after photobleaching could also be tested to
illustrate whether the dark adaption course was delayed only
after photobleaching, as happened in LCA patients after gene
therapy.
In conclusion, our study identified and quantified the
RPE levels of visual cycle-associated proteins in rd12 mice
before and after gene therapy. RPE65 gene delivery restored
RPE65 expression and modified the levels of other functional
proteins implicated in visual cycle. Gene therapy resulted in
incomplete recovery of the levels of RALBP-1 in the RPE of
rd12 mice, indicating that this may also occur in LCA patients
undergoing gene therapy and be one of the main causes of
observed delayed dark adaption.
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